Whoa! How did you get here? This company profile is not meant to be publicly available. Research on this company is incomplete, and the overall rating has been disabled, but while you are here feel free to have a look at the info we do have.
Pharmaceutical sales and marketing
Over the counter products are Azep and Eyezep (allergic Rhinitis), Linicin (head lice), Molaxole (constipation), Waxsol (ear wax).
|Meda Pharmaceuticals Pty Ltd||AUS||website|
| Meda AB
owns 100% of Meda Pharmaceuticals Pty Ltd
| Mylan NV
owns 100% of Meda AB
| » Viatris Inc
owns 100% of Mylan NV
|Meda Pharmaceuticals Pty Ltd|
|No assessment data currently available for Meda Pharmaceuticals Pty Ltd|
This company has a number of sustainability claims on its website, which includes annual Sustainability Reports since 2010.
Source: company website (2015)
In 2020, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to reduce greenhouse gas emissions and mitigate climate change risk. Responding companies are scored across four key areas: disclosure; awareness; management; and leadership. This company received a CDP Climate Change Score of B-.
Source: CDP (2020)
In 2020, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to manage and govern freshwater resources. Responding companies are scored on six key metrics: transparency; governance & strategy; measuring & monitoring; risk assessment; targets & goals; and value chain engagement. This company received a CDP Water Security Score of B.
Source: CDP (2020)
In August 2017, Mylan agreed to a $465 million settlement in a whistleblower lawsuit. The U.S. Justice Department and several states claimed the company overcharged Medicaid for EpiPens. As part of the settlement, Mylan did not have to admit any wrongdoing. The settlement came as Mylan faced growing complaints about skyrocketing price hikes for EpiPens. Between 2007 and 2016, Mylan increased the price of a two-pack of EpiPens from less than $100 to more than $600.
Source: Drug Watch (2017)
This company received a score of 20.2/100 in the Newsweek Green Rankings 2016, which ranks the world's largest publicly traded companies on eight indicators covering energy, greenhouse gases, water, waste, fines and penalties, linking executive pay to sustainability targets, board-level committee oversight of environmental issues and third-party audits. Ranking methodology by Corporate Knights and HIP Investor.
Source: Newsweek (2016)
Changing Markets' 2018 report, 'Hyderabad's Pharmaceutical Pollution Crisis' explores the impacts of pollution from pharmaceutical production sites in the Indian city of Hyderabad, one of the world's largest "bulk drug" manufacturing hubs. Water samples taken by investigators from factories owned by this company found the presence of solvents and/or heavy metals at extremely high concentrations, orders of magnitude higher than maximum regulatory limits or safe exposure levels, which points to substantial human and ecological risk potential.
Source: Changing Markets (2018)
In 2019 the median pay for a worker at this company was US$43,367. The CEO was paid 427 times this amount. Exorbitant CEO pay is a major contributor to rising inequality. CEOs are getting more because of their power to set pay, not because they are increasing productivity or possess specific, high-demand skills. The economy would suffer no harm if CEOs were paid less (or taxed more). In contrast, the CEO-to-typical-worker compensation ratio was 20-to-1 in 1965 and 58-to-1 in 1989.
Source: AFL-CIO (2020)
As You Sow's 2021 report, 'The 100 Most Overpaid CEOs', reveals the 100 most overpaid CEOs from USA's 500 largest public companies (as determined by the S&P 500 list). This company's CEO, Heather Bresch came in at number 21 on the list, having been paid US$18,509,260 in 2020. According to the report, "Most CEOs have come to be grossly overpaid, and that overpayment is harmful to the companies, the shareholders, the customers, the other employees, the economy, and society as a whole."
Source: As You Sow (2021)
Mylan, the makers of the EpiPen, an injectable device that is filled with medicine and can stop a life-threatening allergic reaction with immediate effect, have increased the price of the device from $100 in 2008 to above $500 in 2016, making it a hike of over 400 per cent. Epipens only cost a few dollars to make and the price-hike has caused a public outcry.
Source: news article (2016)
JUST Capital polls Americans every year to identify the issues that matter most in defining just business behaviour. For their 2021 rankings the public identified 19 issues, which are organised under the headings Workers, Communities, Customers, Shareholders and Environment. JUST Capital then define metrics that map to those issues and track and analyse the largest, publicly traded U.S. companies. This analysis powers their rankings, in which this company ranked 295th of 928 companies, and 14th of 51 Pharmaceuticals & Biotech companies.
Source: JUST Capital (2020)
This company received an S&P Global ESG Score of 27/100 in the Pharmaceuticals category of the S&P Global Corporate Sustainability Assessment, an annual evaluation of companies' sustainability practices (last updated 7 Feb 2021). The rankings are based on an analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, environmental reporting, climate strategy, human rights and labour practices.
Source: S&P Global (2021)
This company has corporate social responsibility claims on its website.
Source: company website (2021)
This company is a member of the AMR Industry Alliance, a coalition of biotech, diagnostics, generics and research-based pharmaceutical companies set up to provide sustainable solutions to curb antimicrobial resistance (AMR). AMR is an increasingly significant threat to global public health which puts at risk the effective prevention and treatment of a wide range of infections.
Source: AMR Industry Alliance (2021)
California, the UK and Australia have all enacted legislation requiring companies operating within their borders to disclose their efforts to eradicate modern slavery from their operations and supply chains. Follow the link to see this company's disclosure statement.
Source: company website (2020)
OpenSecrets.org tracks the influence of money on U.S. politics, and how that money affects policy and citizens' lives. Follow link to see this company's record of political donations, lobbying, outside spending and more.
Source: Open Secrets (2020)
|Address||Suite 1, Level 3, 110 Pacific Highway, St Leonards, NSW, 2065, Australia|
|Phone||02 8209 3422|